Nonetheless, numerous authors express varying levels of concern about known side effects for both rapamycin and rapalogs [9,11,12,13,14,15], and the limited effectiveness of rapalogs against cancer has led to their being superseded by other modes of treatment in some cases [15,17] and to the investigation of alternative means of inhibiting TOR activity [13,18]. The gene discussed is RORC; the disease is cancer.